176 related articles for article (PubMed ID: 30989171)
1. A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart disease: new insights for improved secondary prophylaxis strategies.
Hand RM; Salman S; Newall N; Vine J; Page-Sharp M; Bowen AC; Gray K; Baker A; Kado J; Joseph J; Marsh J; Ramsay J; Sika-Paotonu D; Batty KT; Manning L; Carapetis J
J Antimicrob Chemother; 2019 Jul; 74(7):1984-1991. PubMed ID: 30989171
[TBL] [Abstract][Full Text] [Related]
2. High risk of early sub-therapeutic penicillin concentrations after intramuscular benzathine penicillin G injections in Ethiopian children and adults with rheumatic heart disease.
Ketema EB; Gishen NZ; Hailu A; Leul A; Hadgu A; Hagos K; Berhane S; Tsega T; Page-Sharp M; Davis TM; Moore B; Batty KT; Carapetis J; Salman S; Manning L
PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009399. PubMed ID: 34115748
[TBL] [Abstract][Full Text] [Related]
3. Penicillin Dried Blood Spot Assay for Use in Patients Receiving Intramuscular Benzathine Penicillin G and Other Penicillin Preparations To Prevent Rheumatic Fever.
Page-Sharp M; Coward J; Moore BR; Salman S; Marshall L; Davis TME; Batty KT; Manning L
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559267
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic study of benzathine penicillin G administration in Indigenous children and young adults with rheumatic heart disease in the Northern Territory, Australia.
Kado J; Salman S; Hand R; O'Brien M; Ralph A; Bowen AC; Page-Sharp M; Batty KT; Dolman V; Francis JR; Carapetis J; Manning L
J Antimicrob Chemother; 2022 Sep; 77(10):2679-2682. PubMed ID: 35822635
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study.
Kado J; Salman S; Hla TK; Enkel S; Henderson R; Hand RM; Hort A; Page-Sharp M; Batty K; Moore BR; Bennett J; Anderson A; Carapetis J; Manning L
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0096223. PubMed ID: 37971244
[TBL] [Abstract][Full Text] [Related]
6. Adherence to secondary prevention of rheumatic fever and rheumatic heart disease in young people: an 11-year retrospective study.
Liaw J; Gorton S; Heal C; White A
Aust N Z J Public Health; 2022 Dec; 46(6):758-763. PubMed ID: 35616403
[TBL] [Abstract][Full Text] [Related]
7. "Hurts less, lasts longer"; a qualitative study on experiences of young people receiving high-dose subcutaneous injections of benzathine penicillin G to prevent rheumatic heart disease in New Zealand.
Cooper J; Enkel SL; Moodley D; Dobinson H; Andersen E; Kado JH; Barr RK; Salman S; Baker MG; Carapetis JR; Manning L; Anderson A; Bennett J
PLoS One; 2024; 19(5):e0302493. PubMed ID: 38743745
[TBL] [Abstract][Full Text] [Related]
8. Improvement in rheumatic fever and rheumatic heart disease management and prevention using a health centre-based continuous quality improvement approach.
Ralph AP; Fittock M; Schultz R; Thompson D; Dowden M; Clemens T; Parnaby MG; Clark M; McDonald MI; Edwards KN; Carapetis JR; Bailie RS
BMC Health Serv Res; 2013 Dec; 13():525. PubMed ID: 24350582
[TBL] [Abstract][Full Text] [Related]
9. Penicillin concentrations after increased doses of benzathine penicillin G for prevention of secondary rheumatic fever.
Currie BJ; Burt T; Kaplan EL
Antimicrob Agents Chemother; 1994 May; 38(5):1203-4. PubMed ID: 8067767
[TBL] [Abstract][Full Text] [Related]
10. Determining the impact of Benzathine penicillin G prophylaxis in children with latent rheumatic heart disease (GOAL trial): Study protocol for a randomized controlled trial.
Beaton A; Okello E; Engelman D; Grobler A; Scheel A; DeWyer A; Sarnacki R; Omara IO; Rwebembera J; Sable C; Steer A
Am Heart J; 2019 Sep; 215():95-105. PubMed ID: 31301533
[TBL] [Abstract][Full Text] [Related]
11. Rheumatic fever prophylaxis using benzathine penicillin G (BPG): two- week versus four-week regimens: comparison of two brands of BPG.
Kassem AS; Zaher SR; Abou Shleib H; el-Kholy AG; Madkour AA; Kaplan EL
Pediatrics; 1996 Jun; 97(6 Pt 2):992-5. PubMed ID: 8637789
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous administration of benzathine benzylpenicillin G has favourable pharmacokinetic characteristics for the prevention of rheumatic heart disease compared with intramuscular injection: a randomized, crossover, population pharmacokinetic study in healthy adult volunteers.
Kado JH; Salman S; Henderson R; Hand R; Wyber R; Page-Sharp M; Batty K; Carapetis J; Manning L
J Antimicrob Chemother; 2020 Oct; 75(10):2951-2959. PubMed ID: 32696033
[TBL] [Abstract][Full Text] [Related]
13. Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever?
Currie BJ
Pediatrics; 1996 Jun; 97(6 Pt 2):989-91. PubMed ID: 8637788
[TBL] [Abstract][Full Text] [Related]
14. Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease.
Barr RK; Barber BW; Tait JR; Landersdorfer CB; Salman S; Musk GC; Page-Sharp M; Batty KT; Kado J; Manning L; Carapetis JR; Boyd BJ
Eur J Pharm Biopharm; 2023 Aug; 189():240-250. PubMed ID: 37354997
[TBL] [Abstract][Full Text] [Related]
15. A population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults.
Neely M; Kaplan EL; Blumer JL; Faix DJ; Broderick MP
Antimicrob Agents Chemother; 2014 Nov; 58(11):6735-41. PubMed ID: 25182635
[TBL] [Abstract][Full Text] [Related]
16. Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study.
Belay W; Dessie A; Ahmed H; Gedlu E; Mariyo A; Shehibo A; Tigabu Z; Aliyu MH; Soslow J
BMC Cardiovasc Disord; 2022 Feb; 22(1):26. PubMed ID: 35109807
[TBL] [Abstract][Full Text] [Related]
17. Sharing success - understanding barriers and enablers to secondary prophylaxis delivery for rheumatic fever and rheumatic heart disease.
Chamberlain-Salaun J; Mills J; Kevat PM; Rémond MG; Maguire GP
BMC Cardiovasc Disord; 2016 Aug; 16(1):166. PubMed ID: 27581750
[TBL] [Abstract][Full Text] [Related]
18. Qualitative assessment of healthy volunteer experience receiving subcutaneous infusions of high-dose benzathine penicillin G (SCIP) provides insights into design of late phase clinical studies.
Enkel SL; Kado J; Hla TK; Salman S; Bennett J; Anderson A; Carapetis JR; Manning L
PLoS One; 2023; 18(4):e0285037. PubMed ID: 37104500
[TBL] [Abstract][Full Text] [Related]
19. Out-of-pocket expenditure for administration of benzathine penicillin G injections for secondary prophylaxis in patients with rheumatic heart disease: A registry-based data from a tertiary care center in Northern India.
Arvind B; Saxena A; Kazi DS; Bolger AF
Indian Heart J; 2021; 73(2):169-173. PubMed ID: 33865513
[TBL] [Abstract][Full Text] [Related]
20. Effect of benzathine penicillin treatment on antibiotic susceptibility of viridans streptococci in oral flora of patients receiving secondary prophylaxis after rheumatic fever.
Bilavsky E; Eliahou R; Keller N; Yarden-Bilavsky H; Harel L; Amir J
J Infect; 2008 Apr; 56(4):244-8. PubMed ID: 18295897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
